Scientific Publications

Advancing dermatological science.

September 2022

EADV 2022

Long-term Safety and Efficacy of Roflumilast Foam 0.3% in Patients With Seborrheic Dermatitis in a 24–52-week, Open-label Phase 2 Trial

September 2022

EADV 2022

Efficacy and Tolerability of Roflumilast Cream 0.3% in Patients With Chronic Plaque Psoriasis Involvement on the Face, Intertriginous, or Genital Areas: Pooled Results from Phase 3 Trials (DERMIS-1 and DERMIS-2)

September 2022

EADV 2022

Efficacy and Safety by Race and Ethnicity in a Randomized, Double-blind, Vehicle-Controlled, Phase 2a Study Evaluating Once-Daily Roflumilast Foam 0.3% in Patients With Seborrheic Dermatitis

April 2022

AMCP 2022

Effects of Roflumilast Cream on Patient Burden and Work Productivity in Patients With Psoriasis

April 2022

AAD 2022

Pooled Efficacy and Safety Results From the DERMIS-1 and DERMIS-2 Phase 3 Trials of Once-Daily Roflumilast Cream 0.3% by Baseline Body Surface Area

April 2022

AAD 2022

Pooled Efficacy and Safety Results From the DERMIS-1 and DERMIS-2 Phase 3 Trials of Once-Daily Roflumilast Cream 0.3% for Treatment of Chronic Plaque Psoriasis

April 2022

AAD 2022

Efficacy and Safety of Once-Daily Roflumilast Cream 0.3% in Patients With Knee/Elbow Involvement: Pooled Results From Phase 3 Trials (DERMIS-1 and DERMIS-2)

April 2022

AAD 2022

Long-term Safety and Efficacy of Roflumilast Cream 0.3% in Patients With Chronic Plaque Psoriasis: Interim Results From a 24-Week, Phase 3 Open-Label Study

April 2022

AAD 2022

Effect of Roflumilast Foam 0.3% Treatment of Seborrheic Dermatitis on Patient Quality of Life: Results From a Phase 2 Study

September 2021

EADV 2021

Roflumilast Cream 0.3%, Safety and Efficacy in Patients with Chronic Plaque Psoriasis (DERMIS-1 and DERMIS-2)

September 2021

EADV 2021

Roflumilast Foam 0.3% Improved the Severity and Burden of Itch in Patients with Scalp and Body Psoriasis

September 2021

EADV 2021

Roflumilast Cream 0.3% Improved the Severity and Impact of Itch in Patients with Chronic Plaque Psoriasis (DERMIS-1 and DERMIS-2)

Meaningful innovation at a glance.

Download our corporate fact sheet.

Download